Literature DB >> 11283811

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

P Cacoub1, L Geffray, E Rosenthal, C Perronne, P Veyssier, G Raguin.   

Abstract

Several studies have suggested that the progression of hepatitis C virus (HCV) infection is more severe in patients infected by the human immunodeficiency virus (HIV). Two national retrospective multicenter cohort surveys were performed in France that included 17,487 HIV-infected patients during 1995 and 26,497 during 1997. The following data was evaluated: total number of deaths; number of deaths linked to AIDS, cirrhosis, or hepatocellular carcinoma (HCC); and number of deaths related to other (non-HCV--linked) causes. In 1995, the causes of death were as follows: AIDS, 1307 (7.47%); cirrhosis or HCC, 21 (0.12%); and other (non-HCV--linked) causes, 99 (0.56%). In 1997, the causes of deaths were as follows: AIDS, 459 (1.73%); cirrhosis or HCC 36 (0.13%); and other (non-HCV--linked) causes, 48 (0.18%). Comparative results between the 1995 and 1997 surveys showed a dramatic decrease in AIDS-related mortality rates (7.47% vs. 1.73%; P<.001) but not in HCV-related mortality rates (0.06% vs. 0.07%; P=.79). In France, despite the high prevalence of HCV infection in HIV-positive patients, the mortality rate in 1995 and 1997 caused by HCV-related cirrhosis or HCC was low.

Entities:  

Mesh:

Year:  2001        PMID: 11283811     DOI: 10.1086/319747

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections.

Authors:  Chelsey J Judge; Lenche Kostadinova; Kenneth E Sherman; Adeel A Butt; Yngve Falck-Ytter; Nicholas T Funderburg; Alan L Landay; Michael M Lederman; Scott F Sieg; Johan K Sandberg; Donald D Anthony
Journal:  J Leukoc Biol       Date:  2017-04-11       Impact factor: 4.962

Review 2.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

3.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

4.  Unique Cytokine/Chemokine Signatures for HIV-1 and HCV Mono-infection versus Co-infection as Determined by the Luminex® Analyses.

Authors:  Saifur Rahman; John E Connolly; Sharron L Manuel; Jihed Chehimi; Luis J Montaner; Pooja Jain
Journal:  J Clin Cell Immunol       Date:  2011-01-07

5.  Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?

Authors:  Salvador Resino; José M Bellón; Cristina Asensio; Dariela Micheloud; Pilar Miralles; Ana Vargas; Pilar Catalán; Juan C López; Emilio Alvarez; Jaime Cosin; Raquel Lorente; María A Muñoz-Fernández; Juan Berenguer
Journal:  BMC Infect Dis       Date:  2010-08-19       Impact factor: 3.090

6.  During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.

Authors:  Lenche Kostadinova; Carey L Shive; Chelsey Judge; Elizabeth Zebrowski; Anita Compan; Kelsey Rife; Amy Hirsch; Yngve Falck-Ytter; Daniela M Schlatzer; Xiaolin Li; Mark R Chance; Benigno Rodriguez; Daniel L Popkin; Donald D Anthony
Journal:  J Infect Dis       Date:  2016-08-17       Impact factor: 5.226

7.  Epidemiology of gastroenterologic cancer in Henan Province, China.

Authors:  Jian-Bang Lu; Xi-Bin Sun; Di-Xin Dai; Shi-Kuan Zhu; Qiu-Ling Chang; Shu-Zheng Liu; Wen-Jie Duan
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

8.  Efficacy and safety of atazanavir in patients with end-stage liver disease.

Authors:  G Guaraldi; S Cocchi; A Motta; S Ciaffi; M Codeluppi; S Bonora; F Di Benedetto; M Masetti; M Floridia; S Baroncelli; D Pinetti; A Bertolini; G E Gerunda; R Esposito
Journal:  Infection       Date:  2009-05-26       Impact factor: 3.553

9.  Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.

Authors:  Christopher Payan; Adeline Pivert; Patrice Morand; Samira Fafi-Kremer; Fabrice Carrat; Stanislas Pol; Patrice Cacoub; Christian Perronne; Françoise Lunel
Journal:  Gut       Date:  2007-03-15       Impact factor: 23.059

10.  Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections.

Authors:  Daniela M Schlatzer; Julia M Sugalski; Yanwen Chen; Jill Barnholtz-Sloan; Perica Davitkov; Fred E Hazlett; Nicholas Funderburg; Benigno Rodriguez; Michael M Lederman; Scott F Sieg; Mark R Chance; Donald D Anthony
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.